Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $3000.0.

  • Stoke Therapeutics' Other Non Operating Income fell 8928.57% to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $260000.0, marking a year-over-year increase of 16388.21%. This contributed to the annual value of -$247000.0 for FY2024, which is 24879.52% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Other Non Operating Income is $3000.0, which was down 8928.57% from $28000.0 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Other Non Operating Income ranged from a high of $201000.0 in Q4 2024 and a low of -$428000.0 during Q1 2024
  • Moreover, its 4-year median value for Other Non Operating Income was $41000.0 (2023), whereas its average is $9666.7.
  • Over the last 5 years, Stoke Therapeutics' Other Non Operating Income had its largest YoY gain of 39024.39% in 2024, and its largest YoY loss of 111904.76% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Other Non Operating Income (Quarter) stood at $42000.0 in 2022, then fell by 2.38% to $41000.0 in 2023, then skyrocketed by 390.24% to $201000.0 in 2024, then plummeted by 98.51% to $3000.0 in 2025.
  • Its Other Non Operating Income stands at $3000.0 for Q3 2025, versus $28000.0 for Q2 2025 and $28000.0 for Q1 2025.